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Preliminary results were presented in abstract form in the Late Breaking Clinical Science (Clinical Trial Update) session of the European Society of Cardiology Congress in 2017 and in Heart Failure Congress in 2018.

Clinical PerspectiveWhat Is New?Although the overall results of the EchoCRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial indicated futility or even harm of using cardiac resynchronization therapy in patients with heart failure with QRS duration \<130 ms, we discovered that the risk was concentrated among those with larger left ventricular dimensions; conversely patients with longer QRS duration and smaller left ventricular size appeared to benefit from cardiac resynchronization therapy.What Are the Clinical Implications?The assessment of nonelectrical modulators (eg, left ventricular size, sex, and stature) in patients with heart failure may reveal a group with "narrow" QRS duration and smaller ventricles who benefit from cardiac resynchronization therapy.

 {#jah33265-sec-0009}

Assessment of QRS duration (QRSd) is a key selection criterion for cardiac resynchronization therapy (CRT), recognizing that there is a spectrum of responses. Indications reflect the greatest probability for successful therapy with QRSd \>150 ms, less (or no) effect for QRSd \<150 ms, and futility (or possible harm) with QRSd \<130 ms.[1](#jah33265-bib-0001){ref-type="ref"} However, there is increasing recognition that QRSd may be prolonged not only by reduced myocardial conduction velocity (His‐Purkinje lesions) but also by increased left ventricular (LV) dimension acting to extend the "travel distance" of the propagating wavefront.[2](#jah33265-bib-0002){ref-type="ref"} The distinction is important because the former is the target for CRT, but the latter (itself influenced by heart failure \[HF\] remodeling, sex, and body size/height[3](#jah33265-bib-0003){ref-type="ref"}, [4](#jah33265-bib-0004){ref-type="ref"}) limits CRT response.[5](#jah33265-bib-0005){ref-type="ref"} Hence, any given QRSd reflects the sum effect of factors with opposite implications for CRT success, and this balance may differ among individuals with identical QRSd values. The ratio of QRSd/LV size may better index CRT substrate. When applied, this was superior to the unadjusted QRSd in predicting successful CRT measured by short‐term hemodynamic effects or long‐term remodeling among patients with left bundle branch block (LBBB).[3](#jah33265-bib-0003){ref-type="ref"}, [6](#jah33265-bib-0006){ref-type="ref"} Patients with a high index score (relatively large QRSd and small LV size) had higher probability of CRT response compared with those with a low index score (smaller QRS and large LV size) who could worsen with treatment. Interestingly, this calculation explained CRT inefficacy in some patients with LBBB and QRSd \>150 ms (ie, meeting class I CRT indications) and conversely why others (principally women) with narrower QRSd (\<150 ms) were successfully treated by CRT. These observations raise the intriguing notion that some patients with QRSd \<130 ms, together with lower LV dimensions, may also benefit from CRT.

We tested this hypothesis post hoc in the EchoCRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial, which evaluated CRT effect among patients with QRSd \<130 ms and LV dilatation,[7](#jah33265-bib-0007){ref-type="ref"} hypothesizing that patients with larger LV end‐diastolic volume (LVEDV) would deteriorate but those with the highest QRSd/LVEDV would *improve* with CRT. In addition, because among conventionally selected patients undergoing CRT (LBBB and LV ejection fraction \[LVEF\] \<35%), men have greater LV dilation,[3](#jah33265-bib-0003){ref-type="ref"}, [6](#jah33265-bib-0006){ref-type="ref"} and numerically a higher all‐cause mortality was reported in male patients randomized to CRT‐ON in the EchoCRT trial,[8](#jah33265-bib-0008){ref-type="ref"} we assessed interactions of sex with LV size and CRT effect.

Methods {#jah33265-sec-0010}
=======

Study Design and Conduct {#jah33265-sec-0011}
------------------------

The study was approved by an institutional review board at each participating site, and participants gave written informed consent. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. The study protocol and main outcome results of the EchoCRT trial were reported previously.[7](#jah33265-bib-0007){ref-type="ref"} In brief, patients with New York Heart Association class III or IV HF with LVEF of ≤35%, optimized medical therapy with QRSd \<130 ms and LV end‐diastolic diameter ≥55 mm, and echocardiographic evidence of LV dyssynchrony were randomized 1:1 to CRT‐OFF (control) or CRT‐ON. Device‐implanting physicians and physicians involved in the follow‐up were aware of the study group assignment, whereas patients, HF physicians, and study personnel completing the follow‐up assessments were not. The trial was terminated early after interim analysis because of futility in reaching the primary end point and an observed overall increase in mortality in the CRT‐ON group.

The current analysis was directed towards assessment of the impact of LV size and QRSd/LV size ratio on the effect of CRT in the EchoCRT trial cohort. QRSd was determined from a standard 12‐lead ECG recorded at 25 mm/s before implantation, submitted to the ECG Core Laboratory (University of Glasgow, Glasgow, UK), and echocardiographic data from the Echo Core Laboratory (University of Pittsburgh Medical Center, Pittsburgh, PA). All readers were blinded to the treatment group assignment and any clinical data. Correlations between QRSd, LV size, and height were assessed. LV size was derived from preimplantation biplane LVEDV and indexed to height to account for influence of body size (indexed volumes \[mL/m\] are reported throughout this article). Then, enrolled patients were dichotomized by median LVEDV value (LVEDV~Median~). Because LV size generally is larger in male CRT recipients,[3](#jah33265-bib-0003){ref-type="ref"}, [6](#jah33265-bib-0006){ref-type="ref"} and men were the driver for worse outcomes with CRT in the whole EchoCRT trial cohort,[8](#jah33265-bib-0008){ref-type="ref"} we compared CRT effect according to LV size in each sex. We then assessed the quotient QRSd/LVEDV to test the hypothesis that patients with larger QRSd/LVEDV ratios benefited from CRT. Because LV enlargement was a criterion for inclusion (thus restricting the available patient population with lower LVEDV), we compared CRT effects in patients stratified in the top quartile (ie, quartile 4 \[Q4\]; QRSd/LVEDV~Q4~) versus the remainder (ie, quartile 1--quartile 3 \[Q1--Q3\]; QRSd/LVEDV~Q1--Q3~). This permitted identification of the subgroup of patients with the least contribution of LV enlargement to QRS prolongation and evaluation of their outcome according to the randomized treatment.

Outcomes were assessed by the prespecified primary efficacy outcome (combination of death from any cause and first hospitalization for worsening HF) and secondary outcomes (ie, all hospitalizations for worsening HF throughout the study, all‐cause mortality, and cardiovascular mortality).[7](#jah33265-bib-0007){ref-type="ref"} In addition, we measured changes in echocardiographic structural remodeling from baseline to 6 months after implantation. The combination of LVEF increase of ≥5% and LV end‐systolic volume decrease of ≥10% was used as a measure of positive CRT effect.[9](#jah33265-bib-0009){ref-type="ref"} Results were compared between sexes.

Statistical Analysis {#jah33265-sec-0012}
--------------------

The study results were analyzed at the independent Statistical Centre at the Robertson Centre for Biostatistics, University of Glasgow. (One of us \[N.V.\] had full access to all the data in the study and takes responsibility for its integrity and the data analysis.) Baseline characteristics were reported as means and SDs for continuous variables and counts and percentages for categorical variables, and treatment group comparisons were based on 2‐sample *t* test (or Mann‐Whitney test) and χ^2^ (or Fisher\'s exact) tests, as appropriate. For primary and secondary outcome analyses, interactions between treatment effects (CRT‐ON and CRT‐OFF) and selected groups (ie, dichotomized by LVEDV~Median~ and QRSd/LVEDV~Q4~ versus QRSd/LVEDV~Q1--Q3~) were tested for in Cox proportional hazard models. These models included hazard ratios (HRs) with 95% confidence intervals (CIs) that included treatment (CRT‐ON and CRT‐OFF) adjustments for the following baseline characteristics: sex, country, walking distance, quality‐of‐life score, sitting systolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction, history of coronary artery bypass grafting, and diuretic use. (The same characteristics, except sex, were used in independent male/female comparisons, followed by 3‐way test for interaction.) Time‐to‐event curves were estimated using the Kaplan‐Meier method with the log‐rank test. Follow‐up was censored at study closure, date of death, LV assist device implantation, heart transplant, withdrawal from the study, or unavailability for follow‐up, whichever came first.

For structural remodeling analyses, the proportions of patients with events were compared among groups using a χ^2^ test. Tests for interaction were analyzed using a logistic regression model with CRT randomized treatment and baseline LVEDV grouping included as explanatory variables along with an interaction term. Correlations were reported using the Pearson correlation coefficient.

All tests were 2 sided, with *P*\<0.05 considered to be significant.

Results {#jah33265-sec-0013}
=======

A total of 809 patients were randomized in the EchoCRT trial (405 to CRT‐OFF group \[control\] and 404 to CRT‐ON group). The mean follow‐up was 19.4 months for all patients and 19.8 months for surviving patients. The study visit compliance rate among patients was 95.5%. Overall patient characteristics in our substudy (n=796) did not differ from the whole trial cohort[7](#jah33265-bib-0007){ref-type="ref"} (eg, age, 58±13 years; 72% men; New York Heart Association class III, 94%; LVEF, 27±6%; LV end‐diastolic diameter, 66±8 mm; LVEDV \[uncorrected\], 190±59 mL; ischemic cardiomyopathy, 53%; hypertension, 66%; diabetes mellitus, 40%; chronic lung disease, 19%; chronic kidney disease, 13%; QRSd \[Core Laboratory\], 106±13 ms). Correlation (coefficient *r*) of QRSd with LVEDV was 0.32 (*P*\<0.001); LVEDV/height, 0.32 (*P*\<0.001); LVEF, 0.09 (*P*\<0.01); height, 0.04 (*P*=0.32); and body mass index, 0.04 (*P*=0.23). Among patients with available 6‐month follow‐up echocardiograms (CRT‐ON versus CRT‐OFF, n=313 versus n=312), there was a larger proportion demonstrating improvement in LV function with CRT (36.4% versus 28.2%; *P*=0.028), but most patients in each group showed no change or deterioration.

LV Size and Outcome {#jah33265-sec-0014}
-------------------

This study group (796 patients with available echocardiographic studies; CRT‐ON, n=398; and CRT‐OFF, n=398) was dichotomized by LVEDV~Median~/height (105.9 mL/m; interquartile range \[IQR\], 87.1--127.4 mL/m). Group characteristics are contrasted in Table [1](#jah33265-tbl-0001){ref-type="table"}. LV end‐diastolic diameter was 11.6% and LVEDV (uncorrected) was 59.4% greater in LVEDV~≥Median~ versus LVEDV~\<Median~. Patients with LVEDV~≥Median~ were younger, were more frequently men (≈80%) with wider QRSd, had larger body mass index, had less diabetes mellitus, had lower LVEF, and less frequently had underlying ischemic cardiomyopathy. Groups did not differ for dyssynchrony (Table [1](#jah33265-tbl-0001){ref-type="table"}), lead position (Table [2](#jah33265-tbl-0002){ref-type="table"}), or % CRT pacing (97.7±4.85% versus 97.4±4.69%; *P*=0.51).

###### 

Characteristics of Patients at Baseline by LVEDV/Height Grouping

  Variable                                             Less Than Median, n   Less Than Median, statistic   Greater Than or Equal to Median, n   Greater Than or Equal to Median, statistic   *P* Value
  ---------------------------------------------------- --------------------- ----------------------------- ------------------------------------ -------------------------------------------- -----------------------------------------
  Age, y                                               398                   60.9 (11/43)                  398                                  55.1 (13.31)                                 \<0.001
  Men                                                  398                   258 (64.82)                   398                                  316 (79.40)                                  \<0.001
  QRS width (site) ms                                  398                   102.9 (12.37)                 398                                  107.6 (12.83)                                \<0.001
  QRS width (core) ms                                  394                   102.7 (12.00)                 393                                  108.9 (12.36)                                \<0.001
  Walking distance, m                                  390                   310.8 (119.66)                390                                  339.7 (118.41)                               \<0.001
  Quality‐of‐life score                                395                   51.1 (24.27)                  398                                  51.4 (24.47)                                 0.830
  NYHA classification                                                                                                                                                                        
  I                                                    398                   1 (0.25)                      398                                  4 (1.01)                                     [a](#jah33265-note-0003){ref-type="fn"}
  II                                                   398                   4 (1.01)                      398                                  15 (3.77)                                    
  III                                                  398                   379 (95.23)                   398                                  368 (92.46)                                  
  IV                                                   398                   14 (3.52)                     398                                  11 (2.76)                                    
  BNP, pg/mL                                           201                   240.0 (92.00--586.00)         189                                  281.0 (112.00--515.00)                       0.284
  NT‐proBNP, pg/mL                                     184                   915.0 (409.50--2331.0)        191                                  1250.0 (587.00--2373.0)                      0.128
  Sitting SBP, mm Hg                                   398                   118.8 (18.80)                 398                                  118.6 (20.01)                                0.894
  Sitting DBP, mm Hg                                   398                   72.0 (11.48)                  398                                  73.4 (12.42)                                 0.097
  BMI, kg/m^2^                                         397                   29.2 (6.52)                   398                                  32.5 (15.81)                                 \<0.001
  Height, cm                                           397                   170.4 (10.1)                  398                                  172.6 (13.9)                                 0.012
  Ischemic cardiomyopathy                              397                   236 (59.45)                   398                                  191 (47.99)                                  0.001
  Myocardial infarction \>3 mo ago                     398                   170 (42.71)                   398                                  148 (37.19)                                  0.111
  Percutaneous coronary intervention \>3 mo ago        398                   157 (39.45)                   398                                  130 (32.66)                                  0.046
  CABG \>3 mo ago                                      398                   86 (21.61)                    398                                  63 (15.83)                                   0.037
  Hypertension                                         391                   271 (69.31)                   398                                  256 (64.32)                                  0.137
  Prior ischemic stroke or TIA                         396                   51 (12.88)                    394                                  44 (11.17)                                   0.460
  Diabetes mellitus                                    396                   173 (43.69)                   397                                  142 (35.77)                                  0.023
  Chronic lung disease                                 395                   72 (18.23)                    394                                  74 (18.78)                                   0.841
  Chronic kidney disease                               394                   56 (14.21)                    396                                  49 (12.37)                                   0.446
  LVEF biplane, %                                      398                   28.7 (4.93)                   398                                  25.2 (5.55)                                  \<0.001
  LV end‐diastolic diameter, mm                        398                   62.7 (5.48)                   398                                  70.0 (7.42)                                  \<0.001
  LVEDV, mL                                                                  145.7 (26.2)                                                       232.2 (49.9)                                 \<0.001
  Qualified by TDI and/or radial strain dyssynchrony                                                                                                                                         
  TDI only                                             397                   111 (27.96)                   398                                  85 (21.36)                                   0.061
  Radial strain only                                   397                   81 (20.40)                    398                                  100 (25.13)                                  
  TDI and radial strain                                397                   205 (51.64)                   398                                  213 (53.52)                                  
  Medication                                                                                                                                                                                 
  ACE inhibitor or ARB                                 398                   374 (93.97)                   398                                  382 (95.98)                                  0.194
  Aldosterone antagonist                               398                   220 (55.28)                   398                                  257 (64.57)                                  0.007
  β Blocker                                            398                   385 (96.73)                   398                                  384 (96.48)                                  1.000
  Diuretic agent                                       398                   336 (84.42)                   398                                  351 (88.19)                                  0.122

Categorical variable number (percentage) values are reported. Continuous variable mean (SD) values are reported, except for BNP and NT‐proBNP, for which median (interquartile range) values are presented. ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; LV, left ventricular; LVEDV, LV end‐diastolic volume; LVEF, LV fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; TDI, tissue Doppler imaging; and TIA, transient ischemic attack.

*P* value not reported because of small numbers.

###### 

LV Lead Location, by Study Grouping

  Location                Less Than Median (n=332)   Greater Than or Equal to Median (n=316)
  ----------------------- -------------------------- -----------------------------------------
  Study grouping: LVEDV                              
  Basal                   59 (17.8)                  64 (20.3)
  Mid                     214 (64.5)                 207 (65.5)
  Apical                  59 (17.8)                  45 (14.2)
  *P*=0.40                                           

                              Q1--Q3 (n=481)   Q4 (n=160)
  --------------------------- ---------------- ------------
  Study grouping: QRS/LVEDV                    
  Basal                       93 (19.3)        30 (18.8)
  Mid                         315 (65.5)       101 (63.1)
  Apical                      73 (15.2)        29 (18.1)
  *P*=0.68                                     

Data are given as number (percentage). LV indicates left ventricular; LVEDV, LV end‐diastolic volume; and Q, quartile.

CRT did not affect any of the measured outcomes in patients with LVEDV~\<Median~ (Table [3](#jah33265-tbl-0003){ref-type="table"}). In contrast, among patients with LVEDV~≥Median~, the primary outcome was worsened significantly by CRT (Figure [1](#jah33265-fig-0001){ref-type="fig"}A) and there were more deaths, both overall (*P*=0.002) and attributable to cardiovascular causes (*P*=0.001; significant test for interaction *P*=0.036) (Table [3](#jah33265-tbl-0003){ref-type="table"}). When compared, LV structural improvement was better with CRT‐ON in LVEDV~\<Median~ than with CRT‐OFF (38.8% \[n=59\] versus 27% \[n=44\]; *P*=0.025), but unchanged in LVEDV~≥Median~ (but interaction between the CRT treatment and the LVEDV grouping was nonsignificant: *P*=0.34).

###### 

End Point Results by LVEDV Grouping, All Subjects

  End Point                         Subgroup           CRT‐OFF      CRT‐OFF, No. (%) With Event   CRT‐ON       CRT‐ON, No. (%) With Event   Fully Adjusted Hazard Ratio (95% Confidence Interval), *P* Value[a](#jah33265-note-0006){ref-type="fn"}   *P* Value for Interaction Between Randomized Treatment and Groupings
  --------------------------------- ------------------ ------------ ----------------------------- ------------ ---------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Death or HF hospitalization       Less than median   203          54 (26.60)                    195          44 (22.56)                   0.95 (0.62--1.44), 0.793                                                                                  0.056
  Greater than or equal to median   196                48 (24.49)   202                           71 (35.15)   1.64 (1.11--2.42), 0.012                                                                                                               
  Death                             Less than median   203          17 (8.37)                     195          18 (9.23)                    1.19 (0.58--2.44), 0.631                                                                                  0.054
  Greater than or equal to median   196                9 (4.59)     202                           26 (12.87)   3.71 (1.60--8.61), 0.002                                                                                                               
  HF hospitalization                Less than median   203          44 (21.67)                    195          36 (18.46)                   0.96 (0.60--1.53), 0.857                                                                                  0.149
  Greater than or equal to median   196                46 (23.47)   202                           62 (30.69)   1.52 (1.01--2.27), 0.042                                                                                                               
  CVD death                         Less than median   203          11 (5.42)                     195          13 (6.67)                    1.37 (0.58--3.22), 0.477                                                                                  0.036
  Greater than or equal to median   196                6 (3.06)     202                           23 (11.39)   5.26 (1.93--14.30), 0.001                                                                                                              

CRT indicates cardiac resynchronization therapy; CVD, cardiovascular disease; HF, heart failure; and LVEDV, left ventricular end‐diastolic volume.

Hazard ratio (95% confidence interval) adjusted for country, sex, walking distance, quality of life, sitting diastolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction, history of coronary artery bypass grafting, and diuretic use; *P* value from Wald test.

![Cardiac resynchronization therapy (CRT) effect by left ventricular (LV) size: primary outcomes. Primary outcomes (death from any cause or hospitalization for worsening heart failure) are reported in patient groups dichotomized by median values of LV end‐diastolic volume (LVEDV). A, Overall. Left panel: Among patients with LVEDV lower than median (LVEDV ~\<Median~), CRT had no significant effect. Right panel: In contrast, among those patients with LVEDV is higher than or equal to median (LVEDV ~≥Median~), the primary outcome occurred in 71 of 202 patients (35.2%) in the CRT‐ON group vs 48 of 196 patients (24.5%) in the control group (hazard ratio with CRT, 1.64; 95% confidence interval \[CI\], 1.11--2.42; *P*=0.012). B, Men. Left panel: In LVEDV ~\<Median(Men)~, CRT had no significant effect. Right panel: In LVEDV ~≥Median(Men)~, the primary outcome occurred in 54 of 150 patients (36%) in the CRT‐ON group vs 27 of 137 patients (19.7%) in the control group (hazard ratio with CRT, 2.14; 95% CI, 1.30--3.55; *P*=0.003; significant test for interaction with LVEDV ~\<Median\[Men\]~ *P*=0.018). C, Women. CRT had no significant effect in women, with LVEDV ~\<Median(Women)~ (left panel) or LVEDV ~≥Median(Women)~ (right panel).](JAH3-7-e009592-g001){#jah33265-fig-0001}

Sexes were tested separately. Men had larger LVEDV than women (median, 109.6 \[IQR, 91.2--130.6\] versus 96.2 \[80.8--116.3\] mL/m; *P*\<0.001). CRT in men with LVEDV~\<Median(Men)~ had no effect. In contrast, outcomes were significantly worsened by CRT in LVEDV~≥Median(Men)~ (Table [4](#jah33265-tbl-0004){ref-type="table"}; Figure [1](#jah33265-fig-0001){ref-type="fig"}B). The primary outcome was observed more frequently in this group (Figure [1](#jah33265-fig-0001){ref-type="fig"}B). Cardiovascular death and number of patients with HF hospitalizations increased significantly (Table [4](#jah33265-tbl-0004){ref-type="table"}). Thus, during the trial, 21 of 150 patients with LVEDV~≥Median(Men)~ (14%) in the CRT‐ON group experienced cardiovascular death, compared with 4 of 137 (2.9%) in the CRT‐OFF group (HR, 7.85; 95% CI, 2.17--28.32; *P*=0.002; significant test for interaction with LVEDV~\<Median(Men)~ *P*=0.034). The number of patients with HF hospitalizations increased with CRT: 46 of 150 patients with LVEDV~≥Median(Men)~ (30.7%) in CRT‐ON group versus 25 of 137 (18.25%) in the control group (HR, 1.99; 95% CI, 1.17--3.38; *P*=0.011; test for interaction with LVEDV~\<Median(Men)~ *P*=0.039). No significant LV structural changes occurred at 6 months after implantation among men (n=450) with CRT‐ON (n=231) versus CRT‐OFF (n=219) in either LVEDV~≥Median(Men)~ or LVEDV~\<Median(Men)~.

###### 

End Point Results by LVEDV Grouping Separated by Sex

  End Point                         Subgroup           CRT‐OFF      CRT‐OFF, No. (%) With Event   CRT‐ON       CRT‐ON, No. (%) With Event   Fully Adjusted Hazard Ratio (95% Confidence Interval), *P* Value[a](#jah33265-note-0008){ref-type="fn"}   *P* Value for Interaction Between Randomized Treatment and Groupings
  --------------------------------- ------------------ ------------ ----------------------------- ------------ ---------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Men (n=574)                                                                                                                                                                                                                                         
  Death or HF hospitalization       Less than median   148          41 (27.70)                    139          31 (22.30)                   0.95 (0.57--1.58), 0.838                                                                                  0.018
  Greater than or equal to median   137                27 (19.71)   150                           54 (36.00)   2.14 (1.30--3.55), 0.003                                                                                                               
  Death                             Less than median   148          14 (9.46)                     139          15 (10.79)                   1.32 (0.59--2.96), 0.498                                                                                  0.084
  Greater than or equal to median   137                7 (5.11)     150                           24 (16.00)   4.16 (1.57--11.04), 0.004                                                                                                              
  HF hospitalization                Less than median   148          32 (21.62)                    139          23 (16.55)                   0.90 (0.50--1.62), 0.728                                                                                  0.039
  Greater than or equal to median   137                25 (18.25)   150                           46 (30.67)   1.99 (1.17--3.38), 0.011                                                                                                               
  CVD death                         Less than median   148          9 (6.08)                      139          11 (7.91)                    1.35 (0.51--3.61), 0.547                                                                                  0.034
  Greater than or equal to median   137                4 (2.92)     150                           21 (14.00)   7.85 (2.17--28.32), 0.002                                                                                                              
  Women (n=222)                                                                                                                                                                                                                                       
  Death or HF hospitalization       Less than median   55           13 (23.64)                    56           12 (21.43)                   0.61 (0.24--1.54), 0.295                                                                                  0.530
  Greater than or equal to median   59                 21 (35.59)   52                            18 (34.62)   1.13 (0.53--2.44), 0.753                                                                                                               
  Death                             Less than median   55           3 (5.45)                      56           3 (5.36)                     0.70 (0.11--4.27), 0.699                                                                                  0.841
  Greater than or equal to median   59                 2 (3.39)     52                            2 (3.85)     0.63 (0.03--12.19), 0.758                                                                                                              
  HF hospitalization                Less than median   55           12 (21.82)                    56           12 (21.43)                   0.68 (0.27--1.76), 0.430                                                                                  0.730
  Greater than or equal to median   59                 21 (35.59)   52                            17 (32.69)   1.08 (0.50--2.37), 0.838                                                                                                               
  CVD death                         Less than median   55           2 (3.64)                      56           2 (3.57)                     0.44 (0.04--5.48), 0.527                                                                                  0.640
  Greater than or equal to median   59                 2 (3.39)     52                            2 (3.85)     0.63 (0.03--12.19), 0.758                                                                                                              

Three‐way test of interaction of sex with effects of LVEDV/height on CRT effect for outcomes: death/HF hospitalization, *P*=0.23; death, *P*=0.52; HF hospitalization, *P*=0.19; and CVD death, *P*=0.47. CRT indicates cardiac resynchronization therapy; CVD, cardiovascular disease; HF, heart failure; and LVEDV, left ventricular end‐diastolic volume.

Hazard ratio (95% confidence interval) adjusted for country, walking distance, quality of life, sitting diastolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction, history of coronary artery bypass grafting, and diuretic use; *P* value from Wald test.

In women, CRT did not worsen outcomes in LVEDV~≥Median(Women)~ compared with LVEDV~\<Median(Women)~, but analysis is limited by the relatively few patients in each group and paucity of events (Table [4](#jah33265-tbl-0004){ref-type="table"}; Figure [1](#jah33265-fig-0001){ref-type="fig"}C). Among women (n=175), CRT resulted in no change in LVEDV~≥Median(Women)~, but positive structural remodeling occurred in LVEDV~\<Median(Women)~ (46.5% versus 25% in CRT‐OFF; *P*=0.03 \[although test for interaction was nonsignificant {*P*=0.25}\]).

A 3‐way test of interaction to test whether sex influenced effects of LVEDV on the relationship between CRT and outcome found no difference between men and women for any of the end points.

QRSd/LVEDV Ratio and Outcome {#jah33265-sec-0015}
----------------------------

The QRS and LV size analysis population included 787 patients with core laboratory electrocardiographic analyses (396 in CRT‐OFF and 391 in CRT‐ON). Among 621 patients with available echocardiographic data (CRT‐ON versus CRT‐OFF, n=311 versus n=310), there was a larger proportion demonstrating improvement in LV function with CRT at 6 months after CRT (36.3% versus 27.7%; *P*=0.022).

QRSd/LVEDV ratio in the overall population was a median of 0.99 ms/mL per m (IQR, 0.83--1.19 ms/mL per m). QRSd/LVEDV~Q4~ patients, when compared with QRSd/LVEDV~Q1--Q3~ patients, were older and less tall, with a higher proportion of women, had higher LVEF, and more frequently had underlying ischemic cardiomyopathy, lower body mass index, and more diabetes mellitus (Table [5](#jah33265-tbl-0005){ref-type="table"}). LV end‐diastolic diameter was 11.6%, and LVEDV (uncorrected) was 60.5% greater in QRSd/LVEDV~Q1--Q3~ patients compared with QRSd/LVEDV~Q4~ patients. There was no difference between groups for dyssynchrony, QRSd, LV lead position (Table [2](#jah33265-tbl-0002){ref-type="table"}), or %CRT pacing (97.5±4.88% versus 97.6±4.53%; *P*=0.87).

###### 

Characteristics of Patients at Baseline by QRS/LVEDV Grouping, All Subjects

  Variable                                             Q1--Q3, n   Q1--Q3, statistic         Q4, n   Q4, statistic            *P* Value
  ---------------------------------------------------- ----------- ------------------------- ------- ------------------------ -----------------------------------------
  Age, y                                               590         56.3 (12.85)              197     63.1 (11.11)             \<0.001
  Men                                                  590         442 (74.92)               197     123 (62.44)              \<0.001
  QRS width (site) ms                                  590         104.8 (12.81)             197     106.3 (12.85)            0.168
  QRS width (core) ms                                  590         105.5 (12.26)             197     107.0 (13.38)            0.146
  Walking distance, m                                  581         328.5 (119.02)            191     313.7 (120.70)           0.137
  Quality‐of‐life score                                588         51.6 (24.73)              196     49.8 (23.24)             0.362
  NYHA classification                                                                                                         
  I                                                    590         4 (0.68)                  197     1 (0.51)                 [a](#jah33265-note-0010){ref-type="fn"}
  II                                                   590         16 (2.71)                 197     2 (1.02)                 
  III                                                  590         552 (93.56)               197     188 (95.43)              
  IV                                                   590         18 (3.05)                 197     6 (3.05)                 
  BNP, pg/mL                                           292         240.0 (109.00--569.00)    95      226.0 (72.00--540.00)    0.110
  NT‐proBNP, pg/mL                                     276         1167.0 (535.50--2328.5)   94      919.0 (443.00--2356.0)   0.720
  Sitting SBP, mm Hg                                   590         118.2 (19.23)             197     120.3 (19.37)            0.193
  Sitting DBP, mm Hg                                   590         72.9 (12.10)              197     72.4 (11.13)             0.578
  BMI, kg/m^2^                                         590         31.7 (13.57)              196     28.2 (6.28)              \<0.001
  Height cm                                            590         172.2 (12.78)             196     169.2 (10.35)            0.003
  Ischemic cardiomyopathy                              589         301 (51.10)               197     121 (61.42)              0.012
  Myocardial infarction \>3 mo ago                     590         231 (39.15)               197     82 (41.62)               0.539
  Percutaneous coronary intervention \>3 mo ago        590         210 (35.59)               197     75 (38.07)               0.531
  CABG \>3 mo ago                                      590         105 (17.80)               197     42 (21.32)               0.272
  Hypertension                                         587         392 (66.78)               193     129 (66.84)              0.988
  Prior ischemic stroke or TIA                         585         68 (11.62)                196     24 (12.24)               0.815
  Diabetes mellitus                                    588         229 (38.95)               196     82 (41.84)               0.474
  Chronic lung disease                                 585         111 (18.97)               195     35 (17.95)               0.750
  Chronic kidney disease                               587         75 (12.78)                194     28 (14.43)               0.554
  LVEF biplane, %                                      590         26.1 (5.56)               197     29.8 (4.31)              \<0.001
  LV end‐diastolic diameter, mm                        590         68.0 (7.32)               197     61.4 (5.59)              \<0.001
  LVEDV, mL                                                        208.5 (53.8)                      129.9 (23.7)             \<0.001
  Qualified by TDI and/or radial strain dyssynchrony                                                                          
  TDI only                                             590         138 (23.39)               196     56 (28.57)               0.188
  Radial strain only                                   590         142 (24.07)               196     37 (18.88)               
  TDI and radial strain                                590         310 (52.54)               196     103 (52.55)              
  Medication                                                                                                                  
  ACE inhibitor or ARB                                 590         563 (95.42)               197     184 (93.40)              0.263
  Aldosterone antagonist                               590         364 (61.69)               197     108 (54.82)              0.088
  β Blocker                                            590         569 (96.44)               197     192 (97.46)              0.646
  Diuretic agent                                       590         519 (87.97)               197     162 (82.23)              0.041

Categorical variable number (percentage) values are reported. Continuous variable mean (SD) values are reported, except for BNP and NT‐proBNP, for which median (interquartile range) values are presented. ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; LV, left ventricular; LVEDV, LV end‐diastolic volume; LVEF, LF ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; Q, quartile; SBP, systolic blood pressure; TDI, tissue Doppler imaging; and TIA, transient ischemic attack.

*P* value not reported because of small numbers.

After a mean follow‐up of 19.4 months, CRT elicited opposite effects in study groups (Table [6](#jah33265-tbl-0006){ref-type="table"}, Figure [2](#jah33265-fig-0002){ref-type="fig"}). In multivariable analysis, CRT‐ON *increase*d the proportion of patients reaching the primary end point in QRSd/LVEDV~Q1--Q3~ (31.7% in CRT‐ON \[n=300\] versus 24.8% in CRT‐OFF \[n=290\]; HR, 1.47; 95% CI, 1.07--2.02; *P*=0.016), but *decreased* it in QRSd/LVEDV~Q4~ (death/HF hospitalization, 20.9% in CRT‐ON \[n=91\] versus 28.3% in CRT‐OFF \[n=106\]; HR, 0.64; 95% CI, 0.34--1.24; borderline significant test for interaction *P*=0.046). Stronger differences were observed for all‐cause mortality (test for interaction *P*=0.038). Reverse structural remodeling was increased in QRSd/LVEDV~Q4~ (Figure [3](#jah33265-fig-0003){ref-type="fig"}A). Hence, patients in QRSd/LVEDV~Q4~ gained benefit from CRT.

###### 

End Point Results by QRSd/LVEDV Grouping, All Subjects

  End Point                     Subgroup   CRT‐OFF      CRT‐OFF, No. (%) With Event   CRT‐ON       CRT‐ON, No. (%) With Event   Fully Adjusted Hazard Ratio (95% Confidence Interval), *P* Value[a](#jah33265-note-0012){ref-type="fn"}   *P* Value for Interaction Between Randomized Treatment and Groupings
  ----------------------------- ---------- ------------ ----------------------------- ------------ ---------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Death or HF hospitalization   Q1--Q3     290          72 (24.83)                    300          95 (31.67)                   1.47 (1.07--2.02), 0.016                                                                                  0.046
  Q4                            106        30 (28.30)   91                            19 (20.88)   0.64 (0.34--1.24), 0.188                                                                                                               
  Death                         Q1--Q3     290          16 (5.52)                     300          35 (11.67)                   2.53 (1.36--4.72), 0.003                                                                                  0.038
  Q4                            106        10 (9.43)    91                            8 (8.79)     0.74 (0.24--2.31), 0.609                                                                                                               
  HF hospitalization            Q1--Q3     290          66 (22.76)                    300          82 (27.33)                   1.40 (1.00--1.95), 0.050                                                                                  0.104
  Q4                            106        24 (22.64)   91                            15 (16.48)   0.63 (0.31--1.28), 0.203                                                                                                               
  CVD death                     Q1--Q3     290          11 (3.79)                     300          29 (9.67)                    3.13 (1.51--6.47), 0.002                                                                                  0.079
  Q4                            106        6 (5.66)     91                            6 (6.59)     1.00 (0.22--4.59), 1.000                                                                                                               

CRT indicates cardiac resynchronization therapy; CVD, cardiovascular disease; HF, heart failure; LVEDV, left ventricular end‐diastolic volume; Q, quartile; and QRSd, QRS duration.

Hazard ratio (95% confidence interval) adjusted for country, sex, walking distance, quality of life, sitting diastolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction, history of coronary artery bypass grafting, and diuretic use; *P* value from Wald test.

![Cardiac resynchronization therapy (CRT) effect by the ratio of QRS duration (QRSd)/left ventricular (LV) size: primary outcomes. Primary end point (death from any cause or hospitalization for worsening heart failure) is contrasted for treatment effects in patients grouped according to quartile (Q) ranges (QRSd/LV end‐diastolic volume \[LVEDV\]~Q~ ~1--Q3~ vs QRSd/LVEDV~Q~ ~4~). CRT caused deterioration in QRSd/LVEDV~Q1--Q3~ but improvement in QRSd/LVEDV~Q4~ (hazard ratio, 0.64; 95% confidence interval, 0.34--1.24; significant test for interaction *P*=0.046).](JAH3-7-e009592-g002){#jah33265-fig-0002}

![Structural remodeling. Figures depict proportions of patients in each group who demonstrated the combination of left ventricular (LV) ejection fraction increase of ≥5% and LV end‐systolic volume decrease of ≥10% (ie, sustained a positive structural remodeling[9](#jah33265-bib-0009){ref-type="ref"}) in response to cardiac resynchronization therapy (CRT) in patients grouped according to quartile (Q) ranges (QRS duration \[QRSd\]/LV end‐diastolic volume \[LVEDV\]~Q1--Q3~ vs QRSd/LVEDV~Q4~). A, Overall. LV function improved in CRT‐ON vs CRT‐OFF (42.3% \[n=30\] vs 24.1% \[n=21\]) (*P*=0.015) in the Q4 group. In comparison, there was no change in QRSd/LVEDV~Q1--Q3~ (34.6% \[n=83\] in CRT‐ON vs 29.1% \[n=65\] in CRT‐OFF;*P*=0.21; test for interaction *P*=0.17). By sex. Echocardiographic data were available in 175 women (CRT‐ON vs CRT‐OFF, 82 vs 93) and 446 men (CRT‐ON vs CRT‐OFF, 229 vs 217). CRT in men (B) produced no effect, but in women (C), a beneficial effect was seen in QRSd/LVEDV~Q4Women~ (test for interaction *P*=0.02).](JAH3-7-e009592-g003){#jah33265-fig-0003}

Effects in each sex were evaluated separately. QRSd/LVEDV ratio was greater in women (median, 1.1 \[IQR, 0.9--1.3\] ms/mL) versus men (median, 1.0 \[IQR, 0.8--1.2\] ms/mL; *P*\<0.001). Among men, primary or secondary outcomes were unaffected by CRT in QRSd/LVEDV~Q4\ Men~ but significantly worsened in QRSd/LVEDV~Q1--Q3\ Men~ (Table [7](#jah33265-tbl-0007){ref-type="table"}). In women, outcomes were unaffected by CRT in QRSd/LVEDV~Q1--Q3\ Women~ or QRSd/LVEDV~Q4\ Women~ (Table [7](#jah33265-tbl-0007){ref-type="table"}). A 3‐way test of interaction to test whether sex influenced effects of QRSd/LVEDV on the relationship between CRT and outcome found no difference between men and women for any of the end points. (However, the few female patients in QRSd/LVEDV~Q4~ \[CRT‐ON=22; CRT‐OFF=24\] and paucity of events occurring during the time interval assessed may underpower this comparison.) Echocardiographic data were available in 175 women (CRT‐ON versus CRT‐OFF, 82 versus 93) and 446 men (CRT‐ON versus CRT‐OFF, 229 versus 217). No significant changes were observed in men (Figure [3](#jah33265-fig-0003){ref-type="fig"}B). However, CRT elicited significant reverse remodeling in QRSd/LVEDV~Q4\ Women~ (Figure [3](#jah33265-fig-0003){ref-type="fig"}C).

###### 

Outcomes According to QRS/LVEDV, Separated by Sex

  End Point                     Subgroup   CRT‐OFF      CRT‐OFF, No. (%) With Event   CRT‐ON       CRT‐ON, No. (%) With Event   Fully Adjusted Hazard Ratio (95% Confidence Interval), *P* Value[a](#jah33265-note-0014){ref-type="fn"}   *P* Value for Interaction Between Randomized Treatment and Groupings
  ----------------------------- ---------- ------------ ----------------------------- ------------ ---------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Men (n=565)                                                                                                                                                                                                                             
  Death or HF hospitalization   Q1--Q3     204          45 (22.06)                    219          67 (30.59)                   1.62 (1.09--2.41), 0.016                                                                                  0.142
  Q4                            78         23 (29.49)   64                            17 (26.56)   0.83 (0.40--1.74), 0.628                                                                                                               
  Death                         Q1--Q3     204          12 (5.88)                     219          29 (13.24)                   2.49 (1.21--5.15), 0.013                                                                                  0.218
  Q4                            78         9 (11.54)    64                            9 (14.06)    1.28 (0.41--3.94), 0.671                                                                                                               
  HF hospitalization            Q1--Q3     204          40 (19.61)                    219          56 (25.57)                   1.52 (1.00-- 2.32), 0.052                                                                                 0.218
  Q4                            78         17 (21.79)   64                            12 (18.75)   0.82 (0.35--1.93), 0.657                                                                                                               
  CVD death                     Q1--Q3     204          8 (3.92)                      219          23 (10.50)                   2.74 (1.16--6.49), 0.022                                                                                  0.550
  Q4                            78         5 (6.41)     64                            8 (12.50)    1.74 (0.40--7.49), 0.456                                                                                                               
  Women (n=222)                                                                                                                                                                                                                           
  Death or HF hospitalization   Q1--Q3     85           26 (30.59)                    81           24 (29.63)                   1.16 (0.62--2.19), 0.646                                                                                  0.513
  Q4                            29         8 (27.59)    27                            6 (22.22)    0.63 (0.16--2.54), 0.514                                                                                                               
  Death                         Q1--Q3     85           3 (3.53)                      81           4 (4.94)                     1.39 (0.23--8.47), 0.722                                                                                  0.180
  Q4                            29         2 (6.90)     27                            1 (3.70)     0.49 (0.03--8.22), 0.619                                                                                                               
  HF hospitalization            Q1--Q3     85           26 (30.59)                    81           23 (28.40)                   1.12 (0.59--2.13), 0.729                                                                                  0.749
  Q4                            29         7 (24.14)    27                            6 (22.22)    0.79 (0.18--3.58), 0.763                                                                                                               
  CVD death                     Q1--Q3     85           3 (3.53)                      81           4 (4.94)                     1.39 (0.23--8.47), 0.722                                                                                  ...
  Q4                            29         1 (3.45)     27                            0 (0.00)                                                                                                                                            

Three‐way test of interaction of sex with effects of QRS/LVEDV on CRT effect for outcomes: death/HF hospitalization, *P*=0.65; death, *P*=0.79; HF hospitalization, 0.52; and CVD death, *P*=0.98. CRT indicates cardiac resynchronization therapy; Q1‐3, QRSd/LVEDVQ1‐Q3 ; Q4, QRSd/LVEDVQ4; CVD, cardiovascular disease; HF, heart failure; LVEDV, left ventricular end‐diastolic volume; and Q, quartile.

Hazard ratio (95% confidence interval) adjusted for country, walking distance, quality of life, sitting diastolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction, history of coronary artery bypass grafting, and diuretic use; *P* value from Wald test.

Discussion {#jah33265-sec-0016}
==========

Among patients with HF with QRSd \<130 ms in the EchoCRT trial, those with larger LV dimensions deteriorated with treatment, but in contrast those with larger QRSd and smaller LV size appeared to benefit from CRT. Baseline dyssynchrony did not separate these groups.

The QRSd represents the time taken for the electrical wave of myocardial depolarization to move from the His‐Purkinje system through the ventricular myocardium. It is prolonged most obviously by HPS delay (eg, LBBB) but also by increased LV dimension, which increases "path length."[2](#jah33265-bib-0002){ref-type="ref"} LV size itself may increase with cardiomyopathy and larger body size. These correlations have been observed in healthy subjects and in patients with cardiomyopathy and LBBB.[10](#jah33265-bib-0010){ref-type="ref"}, [11](#jah33265-bib-0011){ref-type="ref"}, [12](#jah33265-bib-0012){ref-type="ref"}, [13](#jah33265-bib-0013){ref-type="ref"}, [14](#jah33265-bib-0014){ref-type="ref"} Among patients with normal QRSd with normal LV function, Stewart et al found that each 10 ms increase in QRSd was associated with a 9.2% increase in LVEDV.[13](#jah33265-bib-0013){ref-type="ref"} Moreover, increase in QRSd was associated with greater height (but not body mass index). We report similar, although modest, correlations in our population with HF with "narrow" QRSd (\<130 ms). The correlation of QRSd and LVEDV was 0.32, and the correlation of LVEDV with patient height was 0.30 (thus, reported LVEDV values were normalized for height \[mL/m\]). No sex differences were observed. However, although a prior study of patients with normal QRSd (but no cardiomyopathy) found no significant sex difference across QRSd when linked to LVEDV and height,[13](#jah33265-bib-0013){ref-type="ref"} here in patients with narrow QRS and HF, we discovered a slight (10%) but significant sex difference in QRSd/LVEDV/height. These interactions are important because any given value of QRSd, the determinant of any individual\'s candidacy for CRT, represents a composite result of delayed myocardial conduction (ie, the substrate for CRT) but also increased LV size (mass/volume), which may degrade CRT benefit.[5](#jah33265-bib-0005){ref-type="ref"} The ratio of QRSd/LV size was shown recently to be a better predictor of CRT effect than QRSd alone in patients with LBBB, and it differed between sexes and among individuals.[3](#jah33265-bib-0003){ref-type="ref"}, [6](#jah33265-bib-0006){ref-type="ref"}

Herein, we extended these principles to patients with HF with QRSd \<130 ms. First, we tested the impact of LV size, noting that the EchoCRT trial enrolled patients with LV dilatation (assessed by LV diameter). LV volume ranged widely, but QRSd ranged only slightly. We discovered that CRT effect was neutral in those with LVEDV~\<Median~, but it was deleterious in patients with LVEDV~≥Median~ (Figure [1](#jah33265-fig-0001){ref-type="fig"}). (This observation is consistent with the negative impact of larger LV size on the success of CRT applied for standard indications.[5](#jah33265-bib-0005){ref-type="ref"}) This may explain our prior result that male patients determined the worse outcomes of CRT‐ON for the entire EchoCRT trial cohort[8](#jah33265-bib-0008){ref-type="ref"}: more men were enrolled, and their LV size was larger, but this was not a sex‐specific effect, according to our results. Next, we assessed the impact of QRSd/LV size stratified by quartiles. The primary outcome was worsened among patients treated by CRT in those with lower QRSd/LV size, but it was possibly improved in the highest quartile (QRSd/LVEDV~Q4~) (Figure [2](#jah33265-fig-0002){ref-type="fig"}) (similar to prior observations in patients with LBBB[3](#jah33265-bib-0003){ref-type="ref"}, [6](#jah33265-bib-0006){ref-type="ref"}). Effects on overall death and on structural remodeling indexes were consistent, with CRT benefit in QRSd/LVEDV~Q4~. Notably, although CRT elicited opposite effects in these 2 groups (ie QRSd/LVEDV~Q1‐Q3~ vs QRSd/LVEDV~Q4~), QRSd and echocardiographic dyssynchrony indexes were similar (ie, these were not differentiators). There was a significant sex difference in QRSd/LVEDV ratio: it was greater in women. Despite this favorable substrate, no sex difference between CRT response in QRSd/LVEDV~Q1--Q3~ and QRSd/LVEDV~Q4~ was found in multivariable analysis for the primary and secondary outcomes. Although there were proportionally more women in QRSd/LVEDV~Q4~, they were still a minority (CRT‐ON versus CRT‐OFF, 22 versus 24) and experienced few events, underpowering this comparison. Interestingly, improved structural remodeling in QRSd/LVEDV~Q4~ was largely accounted for by CRT effects in women (Figure [3](#jah33265-fig-0003){ref-type="fig"}).

The demonstration that some patients with QRS \<130 ms may derive benefit from CRT may appear counterintuitive, because CRT aims to reverse delayed LV depolarization, typically LBBB. However, normal QRSd is 85 to 92 ms, and the cut point of 120 ms to select "wide" was arbitrarily defined.[11](#jah33265-bib-0011){ref-type="ref"}, [15](#jah33265-bib-0015){ref-type="ref"}, [16](#jah33265-bib-0016){ref-type="ref"}, [17](#jah33265-bib-0017){ref-type="ref"} Hence, it is conceivable that some patients with QRSd \<130 ms may have significant LV conduction delay that may form the substrate for successful CRT. However, simple QRSd cut points failed to separate subgroups with positive response to CRT in the EchoCRT trial, as reported previously.[18](#jah33265-bib-0018){ref-type="ref"} Outcomes of patients with QRSd 120 to 130 ms did not differ from those with QRSd \<120 ms. Elsewhere, it is well appreciated that accepted LBBB criteria may be seen with QRSd \<130 ms, usually in women with smaller stature, and CRT may be beneficial, an effect attributed to smaller heart size.[11](#jah33265-bib-0011){ref-type="ref"} Inclusion of height (and presumably its effect on LV size) in an individual patient meta‐analysis of randomized CRT trials supported CRT benefit for patients of shorter stature and QRS \<130 ms.[4](#jah33265-bib-0004){ref-type="ref"} Conversely, a nonresponse rate of \>20% persisted among patients undergoing CRT with class I indications (LBBB and QRS \>150 ms), minimal comorbidities, and well‐sited LV leads, an effect at least partially attributable to excessive LV dilatation.[3](#jah33265-bib-0003){ref-type="ref"} Collectively, these reports may explain why QRSd alone is an incomplete predictor of CRT response. Although this influence of LV size on QRSd is recognized in electrocardiographic guidelines,[2](#jah33265-bib-0002){ref-type="ref"} it has not been included in the electrocardiographic criteria exercised for CRT selection.

Our results have significant implications. There has been recurring interest in transferring the well‐established benefits of CRT in patients with HF with a wide QRSd to those with narrow QRSd (\<130 ms), who account for most patients with HF. Despite anecdotal experience and initial promise from small studies selecting narrow QRSd patients on the basis of echocardiographic evidence of dyssynchrony, results from subsequent randomized trials have been disappointing.[19](#jah33265-bib-0019){ref-type="ref"} Indeed, the overall results of the EchoCRT trial pointed to futility of CRT. The current study shows that inclusion of LV dimension and height in conjunction with QRSd separated groups who were harmed versus others who may gain benefit. Because the trial required LV dilation for enrollment, male patients (72%) dominated the cohort and determine overall trial results. Under these conditions, the isolation of a minority sustaining a positive effect is all the more striking. Because this group was characterized by smallest LV size, and the trial excluded patients with LV diastolic diameter \<55 mm, it likely underrepresents the fraction of patients with HF with QRS \<130 ms but high QRSd/LVEDV ratio in the community.

Strengths and Limitations {#jah33265-sec-0017}
=========================

Although conducted post hoc, this analysis assessed prespecified end points using prospectively collected data sets, requiring no additional review or imputation. Electrocardiographic and echocardiographic data were adjudicated in core laboratories. Analyses were investigator driven (N.V.) and conducted independently without involvement of the sponsor. However, our conclusions should be interpreted as hypothesis generating, because the trial was prematurely terminated, reducing the statistical power of any subgroup analysis and tests for interactions. QRSd/LVEDV ratio was not a stratification factor at trial entry but LV dilatation was, greatly reducing the number of patients with smaller ventricles and the proportion of female enrollees (ie, our interest groups). We indexed LVEDV to height. Indexing LV volumes to body size has not been consistently followed in CRT studies and may contribute to differing conclusions of efficacy among different studies.[20](#jah33265-bib-0020){ref-type="ref"} Structural remodeling data are restricted to baseline to 6‐months postimplantation comparison in 621 patients (ie, 78% of the cohort) and not aligned with outcome measures that were assessed at 19 months. Separating contributions to QRSd into either increased path length (size) or conduction slowing by ratio is an approximate method. HF remodeling is a complex process affecting cardiomyocyte and interstitium. Impulse propagation may be affected by LV dilatation but also at tissue, cellular, and subcellullar levels. Thus fibrosis, scar, and reduced intercellular coupling will affect conduction velocity as well as path length. We can only speculate on mechanisms. LV epicardially paced wave fronts during CRT generally propagate more slowly than normal intrinsic conduction and are negatively inotropic, even in normal myocardium.[21](#jah33265-bib-0021){ref-type="ref"} This action may be exaggerated in dilated LVs without myocardial conduction delay, and risks harm. On the contrary, when myocardial conduction is retarded, the same stimulation in a smaller ventricle may restore electrical synchrony and be clinically beneficial.

Conclusion {#jah33265-sec-0018}
==========

In the EchoCRT trial, enrolled patients displayed large heterogeneity in LV size, and the negative effects of CRT were concentrated in men with larger ventricles. Conversely, CRT appeared to be beneficial in a minority with smallest indexed LV volumes. These results add to the growing body of data that QRSd assessment for CRT selection should include attention to the nonelectrical modulating influences of LV size, sex, and stature.[3](#jah33265-bib-0003){ref-type="ref"}, [4](#jah33265-bib-0004){ref-type="ref"}, [6](#jah33265-bib-0006){ref-type="ref"} The hypothesis that CRT may be beneficial in patients with HF with narrow QRSd and smaller ventricles merits prospective evaluation.
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